Floatz logo

STAMULUMAB

Becker Muscular Dystrophy

Wyeth is now a wholly owned subsidiary of Pfizermonoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Becker Muscular Dystrophy cohort.

Asset / SponsorPhaseRating
(-)-Epicatechin
Craig McDonald, MD
Phase 2BB
Tadalafil
Cedars-Sinai Medical Center
Phase 4BB
CARVEDILOL
Catholic University, Italy
Phase 4BB
Ataluren
PTC Therapeutics
Phase 3BB
Lisinopril
Cooperative International Neuromuscular Research Group
Phase 2/3B

View all 19 →

Same molecule, other indications

STAMULUMAB is also rated in:

facioscapulohumeral muscular dystrophyDormant
CCC
Indicative ·
52 / 100
View asset →
limb-girdle muscular dystrophyDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →